Impel NeuroPharma

25 articles with Impel NeuroPharma

• Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

  5/17/2019

  Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock the full potential of proven medicines for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced a poster presentation at the upcoming American Psychiatric Association (APA) Annual Meeting,

• Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

  4/30/2019

  Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel's Nasal Drug Candidate for Acute Migraine

• 

  World Parkinson’s Day: How Science Is Battling the Disease

  4/11/2019

  April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
• 

  BioForest Hotbed: The Fastest-Growing Life Science Market

  3/14/2019

  A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.

• Impel NeuroPharma Appoints Jennifer L. Berman As Vice President Of Marketing

  2/19/2019

  Significant Leadership Experience in CNS Marketing to Help Impel Evolve into a Fully-Integrated R&D and Commercial Organization

• Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

  1/6/2019

  Data Demonstrated Nasal Delivery of INP105 (POD-olanzapine) Achieved Peak Olanzapine Plasma Levels Twice as Fast as Intramuscular Injection, Ten-Times Faster than Orally-Disintegrating Tablets

• Impel NeuroPharma Closes $67.5 Million Series D Financing

  12/6/2018

  Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson's Disease and Acute Agitation

• 

  Impel NeuroPharma Closes $67.5 Million Series D to Advance CNS Portfolio

  12/6/2018

  Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million. It was co-led by KKR and Northwest Venture Partners. Existing investors Vivo Capital, 5AM Ventures and venBio Partners also participated.

• Impel NeuroPharma Appoints Ellen A. Lubman As Chief Business Officer

  11/7/2018

  Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (CNS) disorders with unmet medical needs, today announced the appointment of Ellen A. Lubman as Chief Business Officer.

• Impel Neuropharma Announces First Patient Dosed In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine Headache

  8/22/2018

  Safety and Tolerability of POD-DHE (STOP-301) Trial to Explore Safety and Tolerability of Long-Term Intermittent Use of Intranasal Dihydroergotamine Mesylate Delivered via Precision Olfactory Delivery (POD®) Device

• Impel NeuroPharma Strenthens Leadership Team With Appointment Of Lynn C. Gold As Senior Vice President Of Regulatory Affairs

  7/16/2018

  Impel NeuroPharma announced that Lynn C. Gold, Ph.D., has joined the Company as the Senior Vice President of Regulatory Affairs.

• 

  Impel NeuroPharma Announces FDA Clearance of IND for Pivotal Phase 3 Study of INP104 for Acute Tr...

  6/22/2018

  Impel expects to commence enrollment in the pivotal Phase 3 study evaluating the safety and tolerability of long-term, intermittent use of INP104 for the treatment of acute migraine headache in H2 2018.

• Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson's Disease OFF Episodes

  5/31/2018

  Impel NeuroPharma today announced the initiation of a Phase IIa study designed to explore the safety and pharmacodynamic effect of intranasal levodopa in Parkinson's disease (PD) patients during an OFF episode compared to placebo.

• Impel NeuroPharma Announces Positive Results of Phase I Clinical Trial of INP104 for Treatment of Acute Migraine Headache

  2/7/2018

  INP104 is a novel dihydroergotamine product dosed via Impel's proprietary Precision Olfactory Delivery, or POD, intranasal delivery device.

• Impel NeuroPharma Announces First Patient Dosed in Phase I Clinical Trial of INP104 for Treatment of Acute Migraine Headache

  10/31/2017

  The Phase I trial will investigate the comparative bioavailability of INP104 versus two approved DHE formulations.

• Seattle's Impel NeuroPharma Taps Former Nivalis CEO As New Leader

  10/3/2017

• Veteran Biotech Executive Timothy S. Nelson Joins Impel NeuroPharma's Board Of Directors

  3/3/2017

• Impel NeuroPharma Partners With Camargo Pharmaceutical Services For Development Programs

  2/7/2017

• Seattle Biotech Impel NeuroPharma Bags $36 Million to Advance Drug Delivery Platform for Central Nervous System Disorders

  12/2/2016

• Impel NeuroPharma Announces $36M Funding To Advance Novel Drug Delivery Platform For Central Nervous System Disorders

  12/2/2016